RT Journal Article
SR Electronic
T1 A protocol for the economic evaluation of the smoking Cessation in Pregnancy Incentives Trial III (CPIT III)
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e038827
DO 10.1136/bmjopen-2020-038827
VO 10
IS 10
A1 Nicola McMeekin
A1 Lesley Sinclair
A1 Linda Bauld
A1 David Michael Tappin
A1 Alex Mitchell
A1 Kathleen Anne Boyd
YR 2020
UL http://bmjopen.bmj.com/content/10/10/e038827.abstract
AB Introduction Smoking results in an average 10-year loss of life, but smokers who permanently quit before age 40 can expect a near normal lifespan. Pregnancy poses a good opportunity to help women to stop; around 80% of women in the UK have a baby, most of whom are less than 40 years of age. Smoking prevalence during pregnancy is high: 17%–23% in the UK. Smoking during pregnancy causes low birth weight and increases the risk of premature birth. After birth, passive smoking is linked to sudden infant death syndrome, respiratory diseases and increased likelihood of taking up smoking. These risks impact the long-term health of the child with associated increase in health costs. Emerging evidence suggests that offering financial incentives to pregnant women to quit is highly cost effective.This protocol describes the economic evaluation of a multi-centre randomised controlled trial (Cessation in Pregnancy Incentives Trial III, CPIT III) designed to establish whether offering financial incentives, in addition to usual care, is effective and cost effective in helping pregnant women to quit.Methods and analysis The economic evaluation will identify, measure and value resource use and outcomes from CPIT III, comparing participants randomised to either usual care or usual care plus up to £400 financial incentives. Within-trial and long-term analyses will be conducted from a National Health Service and Personal Social Services perspective; the outcome for both analyses will be quality adjusted life-years measured using EQ-5D-5L. Patient level data collected during the trial will be used for the within-trial analysis, with an additional outcome of cotinine validated quit rates at 34–38 weeks gestation and 6 months postpartum. The long-term model will be informed by data from the trial and published literature.Trial registration number ISRCTN15236311; Pre-results (https://doi.org/10.1186/ISRCTN15236311).